#	year	first author	country of origin	income group	study design	type	setting	sample size (n)	age category	age (years)	male/female	gender ratio
1	2021	Fernandes	United States	high	cohort	retrospective and prospective	8 pediatric hospitals	281	Mixed	10 (1-17)	170/111	1.5
6	2015	Papageorgiou	Greece	high	case control	prospective	pediatric clinic	100	Infants, children	2.1 ± 1.1	44/56	0.8
8	2019	Jinkawa	Japan	high	observational			64	Infants, children	2.1 (0.1-10.4)	36/28	1.3
9	2021	Williams	India	lower middle	observational	prospective	tertiary care teaching hospital	72	Children	5 (3-8)	45/27	1.7
11	2017	Higgins	United States	high	observational	retrospective	pediatric hospital	28	Mixed	10.3 ± 5.5	13/15	0.9
12	2006	Widness	Austria	high	RCT	prospective		29	Neonates	0.06 ± 0.008	16/13	1.2
14	2020	Xu	China	upper middle	observational	retrospective	pediatric hospital	285	Infants, children	1.7 (1-5)	180/105	1.7
15	2021	Karimi	Iran	lower middle	observational	retrospective	3 referral immunodeficiency centers	33	Children, adolescents	6.7 (2.3-16.5)	19/14	1.4
17	2021	Balagurunathan	India	lower middle	observational	retrospective and prospective	tertiary care teaching hospital	21	Mixed	6.9 ± 4	15/6	2.5
18	2018	Mohan	India	lower middle	RCT	prospective	college hospital	60	Neonates	neonates		0
19	2021	Alshengeti	Saudi Arabia	high	observational	retrospective	2 pediatric hospitals	106	Mixed	3.2 ± 3.8	52/54	1
25	2021	Penner	United Kingdom	high	cohort	retrospective	tertiary pediatric hospital	46	Children, adolescents	10.2 (8.8-13.3)	30/16	1.9
26	2021	Emeksiz	Turkey	upper middle	observational	retrospective	PICU	27	Children, adolescents	9 (7-13)	17/10	1.7
28	2021	Hammad	Egypt	lower middle	observational	prospective	pediatric cancer hospital	76	Mixed	9 (1-18)	42/34	1.2
29	2019	Choi	South Korea	high	case control	prospective	pediatric university hospital	123	Mixed	5 (1-17)	70/53	1.3
31	2020	Ling	China	high	case control	retrospective	respiratory department of a pediatric hospital	345	Children	8 (4-6)	194/151	1.3
32	2021	Astagimath	India	lower middle	observational	retrospective	tertiary care hospital	54	Mixed	1-15		0
37	2020	Torres	Chile	high	observational	retrospective and prospective	3 public pediatric reference hospitals	27	Mixed	6 (0-14)	14/13	1.1
38	2017	Muzaheed	Pakistan	lower middle	observational		university laboratory	916	Mixed	7.1 ± 2.5	612/304	2
41	2019	Güngör	Turkey	upper middle	observational	retrospective	university department	44	Mixed	8.8 ± 2.9		0
43	2020	Williams	India	lower middle	observational	prospective	tertiary care teaching hospital	202	Children	5 (2.5-8)	109/93	1.2
44	2021	Mottaghipisheh	Iran	lower middle	observational	prospective	tertiary oncology referral center	60	Infants, children	0.9 (0.3-3.0)	34/26	1.3
45	2021	Turay	Turkey	upper middle	case control	retrospective	university department	97	Mixed	1.7 ± 1	31/66	0.5
47	2021	Alfraij	Kuwait, Saudi Arabia	high	cohort	retrospective	8 pediatric centers	25	Infants, children	2.8 (0.2-8.5)	15/10	1.5
53	2021	Acevedo	Colombia	upper middle	cohort	prospective	14 PICUs	78	Infants, children	7 (1-11)	46/32	1.4
54	2021	Yang	Taiwan	high	observational	retrospective	university hospital	12	Children	4.9 (2.5-6.3)	5/7	0.7
55	2021	Tiwari	India	lower middle	cohort	prospective	2 tertiary care hospitals	41	Mixed	6.2 ± 4.0	23/18	1.3
57	2021	Atay	Turkey	upper middle	observational	retrospective	PICU	41	Children, adolescents	10 (2-20)	33/8	4.1
59	2020	Lee	United States	high	observational	retrospective	pediatric hospital	28	Mixed	9 (0.1-17)	16/12	1.3
60	2021	Valverde	17 European countries	high, upper middle	real-time internet-based survey	prospective	55 centres	286	Children	8.4 (3.8-12.4)	194/92	2.1
64	2020	Pereira	Brazil	upper middle	observational	cross-sectional	university hospital	66	Mixed	0.01-17.62	33/33	1
65	2017	Fitzgerald	United States	high	phase I/IIA Clinical Trial	prospective	pediatric hospital	39	Children, adolescents	11 (5-22)	20/19	1.1

66	2020	Pouletty	France	high	observational	retrospective	7 hospitals	16	Children	10 (4.7-12.5)	8/8	1
68	2020	Kurokawa	Japan	high	observational	retrospective	university hospital	69	Children, adolescents	8.4 (2.1-17.7)	44/25	1.8
69	2019	Horvat	United States	high	cohort	retrospective	PICU	297	Children, adolescents	10.4 (3.2-15.8)	141/156	0.9
73	2020	Clark	United States, Spain, United Kingdom,	high, lower middle	observational	retrospective	6 hospitals	55	Mixed	7 ± 5.2	34/21	1.6
74	2017	Tonial	Spain	high	cohort	prospective	PICU	20	Mixed	0.5 ± 0.2	12/8	1.5
77	2021	Tonial	Brazil	upper middle	observational	retrospective	PICU	294	Infants, children	2.3 (0.9-6.5)	161/133	1.2
78	2020	Pal	India	lower middle	observational	retrospective	university department	31	Children	5.25	17/14	1.2
80	2020	Tonial	Brazil	upper middle	cohort	retrospective	PICU	312	Infants, children	2.0 (0.9-5.6)	171/141	1.2
81	2021	Klymet	Turkey	upper middle	observational	retrospective	university hospital	58	Mixed	6 (0.2-16)	38/20	1.9
83	2017	Carcillo	United States	high	cohort	prospective	PICU	100	Mixed	5.8 ± 5.7	53/47	1.1
85	2019	Simon	United States	high	observational	prospective	PICU	75	Mixed	6.2 ± 6.0	42/33	1.3
88	2016	Al-Ghananim	United States	high	observational	retrospective	NICU	26	Neonates	neonates	11/15	0.7
89	2012	Demirkol	Turkey	upper middle	cohort		8 critical care study group	23	Mixed	7.2 ± 3.6	17/6	2.8
91	2017	Carcillo	United States	high	cohort	prospective	PICU	100	Mixed	5.82 ± 5.69	53/47	1.1
94	2021	Aydin	Turkey	upper middle	observational	retrospective	clinic	39	Mixed	6.10 ± 4.52	25/14	1.8
95	2019	Cui	China	high	case control	prospective	PICU	69	Infants, children	1 (0.8-4)	42/27	1.6
96	2016	Ellis	Puerto Rico	high	case control	retrospective and	4 facilities	110	Mixed	1 (0.2-17.9)	66/44	1.5
97	2021	Abrams	United States	high	surveillance study	retrospective	CDC	1080	Children	8 (4-12)	602/476	1.3
98	2018	Goldman	United States	high	cohort	retrospective	PICU	43	Mixed	5.1 (0.04-17.5)	16/27	0.6
99	2011	Bennett	United States	high	cohort	retrospective	pediatric hospital	171	Mixed	9.3 ± 6.3	98/73	1.3
101	2012	Amin	United States	high	observational	prospective	NICU	140	Neonates	neonates	67/73	0.9
102	2021	Cattalini	Italy	high	observational	retrospective	3 tertiary pediatric hospitals	149	Infants, children	3 (1-6)	84/65	1.3
103	2018	Ghosh	India	lower middle	observational	prospective	tertiary hospital	42	Infants, children	2.5 (1.1-7.2)	22/20	1.1
104	2016	Cui	China	high	nonrandomized concurrent control trial	prospective	PICU	33	Mixed	3.5 ± 4.2	20/13	1.5
106	2020	Deep	United Kingdom	high	observational	retrospective	15 PICUs	116	Children, adolescents	11 (7-14)	76/40	1.9
107	2008	Mäkelä	Finland	high	observational	prospective	NICU	97	Neonates	neonates	52/45	1.2
108	2008	Allen	United States	high	observational	retrospective	pediatric hospital	330	Mixed	6.6 (1-16)	163/167	1
109	2021	Jat	India	lower middle	observational	retrospective	5 centers	402	Children	7 (2-11)	247/155	1.6
110	2017	Ochiai	Japan	high	observational	prospective	NICU	176	Neonates	neonates	86/90	1
113	2007	Garcia	Brazil	upper middle	cohort	prospective	PICU	36	Infants, children	0.5 (0.2-8.3)	24/12	2
114	2021	Sa	United Kingdom	high	observational	cross-sectional	pediatric hospital	75	Mixed	10 (7.9)	50/25	2
115	2014	Minoia	Italy	high	cohort	retrospective	multinational multicenter	362	Children	5.3 (2.7-10.1)	154/208	0.7
124	2004	Haiden	Austria	high	RCT	prospective	NICU	40	Neonates	neonates	19/21	0.9
127	2003	Jacobs	United States	high	RCT	prospective	pediatric hospital	44	Mixed	3.5 ± 1.1	30/14	2.1
	all ferritin values expressed in ng/mL unit											

AKI: acute kidney injury, AUC: area under the curve, COVID-19: coronavirus disease 2019, DIC: disseminated intravascular coagulation, ELISA: enzyme-linked immunosorbent assay, FS: febrile seizure, HBD: hepatobiliary dysfunction, HCT: hematopoetic cell transplantation, HF: heart failure, ICU: intensive care unit, IEI: inborn errors of immunity, IPH: idiopathic pulmonary hemosiderosis, HLH: hemophagocytic lymphohistiocytosis, KD: Kawasaki disease, MAS: macrophage activation syndrome, MISC: multisystem inflammatory syndrome in children, MODS: multiple organ dysfunction syndrome, MOF: multiple organ failure, PIMS-TS: paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2, PCR: polymerase chain reaction, ROC: receiver operating characteristic, SARS-CoV 2: severe acute respiratory syndrome coronavirus 2, sJIA: systemic juvenile idiopathic arthritis, TPE: therapeutic plasma exchange, VL: visceral leishmaniasis

#	year	first author	ferritin definition	ferritin threshold	AUC (95%CI)	sensitivity (%)	specificity (%)	normal range	increased (%)	normal (%)	decreased (%)	ferritin statistics	timing	overall statistics	case/intervention	control/comparator	diagnosis/condition	outcome	analysis description	significancy	analysis
1	2021	Fernandes	MISC: elevation of ferritin	500					87/170 (51.2)			frequency	peak				COVID-19, MISC	severity		no	Fisher exact test
6	2015	Papageorgiou	iron deficiency: ≤30	30							14/100 (14)	mean ± SD	baseline		48.61 ± 36.63	74.03 ± 38.04	febrile seizure	iron deficiency	complex FS vs simple FS and control	yes	independent t-test, Chi square
8	2019	Jinkawa	disease activity in KD and MAS, MAS: >684	684					5/5 (100)			mean ± SD	baseline		8741 ± 8181.5		MAS in KD				
9	2021	Williams	hyperferritinemia: >500, mild: 500-2000, moderate: > 2000-10000, and severe: >10000	**2000**	0.56 (0.35-0.78)	50	73	<500	45/62 (72.6)	17/62 (27.4)		median (IQR)	baseline	668 (420-2714)	1806 (443-4727)	666 (382-2653)	scrub typhus	mortality		no	ROC curves, Mann-Whitney test
11	2017	Higgins	iron deficiency in adult HF: <100	100							26/28 (92.9)	mean ± SD	baseline	45 ± 30			HF secondary to dilated cardiomyopathy	mortality	base-2 logarithm	yes	relative risk regression
12	2006	Widness	iron storage	15							7/18 (38.9)	mean ± SD	baseline		351 ± 55	310 ± 32	very preterm, very low birth weight infants				
14	2020	Xu										mean ± SD	baseline		1945 ± 1001	465 ± 195	adenoviral pneumonia	severity		yes	t-test
15	2021	Karimi										median (IQR)	not given	413 (95-1500)	800 (800-2037)	125 (78-413)	COVID-19 in IEI	mortality		yes	Mann-Whitney test
17	2021	Balagurunathan		500					9/21 (42.9)			frequency	not given				MISC	hospital stay ≥7 days		yes	univariate analysis
18	2018	Mohan	iron store									mean ± SD	post-intervention		244.853 ± 187.334	148.542 ± 161.961	neonates requiring resuscitation				
19	2021	Alshengeti		500				<500		30/35 (85.7)	5/35 (14.3)	mean ± SD	not given	424.35 ± 763.85			COVID-19				
25	2021	Penner	systemic inflammation: >300	300				15.1-70.0				median (IQR)	baseline	915 (475-1650)			PIMS-TS				
26	2021	Emeksiz	evidence of inflammation: >140	140				7-140				median (IQR)	baseline	535 (326.8-1533.1)	1435 (445.5-1744)	438.5 (226.3-671.5)	MISC	determinant	TPE vs non-TPE	yes	Wilcoxon test
28	2021	Hammad	high: >1000	1000					50/74			frequency	not given				COVID-19 in	severity		yes	Chi-square or Fisher's exact test
29	2019	Choi		**230**		67	67					median	not given		35.95		Mycoplasma pneumoniae pneumonia	refractory		yes	ROC curves, Mann-Whitney U test
31	2020	Ling		**171.15 (ROC), 174.15 (logistic regression)**	0.806	82.4	69.3					mean ± SD	baseline		421.61 ± 341.06	150.85 ± 167.70	Mycoplasma pneumoniae pneumonia	hypoxia	MPP with hypoxia vs general MPP	yes	ROC curves, logistic regression
32	2021	Astagimath						24-336 (male), 11-307 (female)				mean ± SD	not given	167.2 ± 256.6			COVID-19				
37	2020	Torres										median (IQR)	not given	309 (156-696)	542 (135-835)	230 (156-298)	MISC	ICU admission		no	Mann–Whitney rank sum test
38	2017	Muzaheed	iron excess									mean ± SD	not given	4989.3 ± 1978.3	3849.5 ± 1513.5	6413.5 ± 2103.9	severe sepsis in transfusion dependent thalassemia	bacterial infection		yes	t-test
41	2019	Güngör	deficient: ≤30, normal: 31-99, high: ≥100	**93.5**	(0.773-0.989)	92.9	66.2	31-99				mean ± SD	not given		1503.50 ± 2280.44	57.43 ± 35.96	Wilson's disease	fulminant	fulminant vs asymptomatic	yes	ROC curves, Pearson Correlation test
43	2020	Williams	hyperferritinemia: >500	**500**	0.53 (0.53-0.67)	62	36	≤500	124/183 (67.8)	59/183 (32.2)		median (IQR)	baseline	798 (378-3205)	1381 (433-5410)	707 (365-2937)	sepsis	28 days mortality		no	ROC curves, student t-test
44	2021	Mottaghipisheh	high: >500, extreme hyperferritinemia: >10000	500					60/60 (100)			median (range)	baseline	4825 (2000.0-10324.5)	7122 (3226.2-33112.2)	3618 (1990.2-9479.2)	HLH	secondary to VL	VL-associated vs primary	yes	Mann-Whitney U test
45	2021	Turay										mean ± SD	not given	28 ± 32	41 ± 54	22 ± 16	febrile seizure	complex FS	complex vs simple FS	yes	independent samples t-test
47	2021	Alfraij										mean ± SD	baseline	1229 ± 1689	587 ± 796	1358 ± 1807	COVID-19	mortality		no	unpaired t-test
53	2021	Acevedo		500					39/78 (50)			frequency	not given				MISC	mortality		yes	logistic regression
54	2021	Yang	iron definition: <12 (<5 years), <15 (≥5 years)									median (IQR)	baseline	141.3 (27.9-188.0)	320 (98.8-619)	38.7 (12.7-60.2)	IPH	ICU admission		yes	stepwise multiple regression analysis
55	2021	Tiwari	high: >300	300					22/41 (54)			median (IQR)	peak	350 (170-733)	1178.0 (717.0-23840.0)	266.0 (153.0-555.0)	MISC	mechanical ventilation requirement		yes	Mann-Whitney test
57	2021	Atay										median (IQR)	not given		1200 (367-22627)	332.5(16-3274)	MISC	PICU admission		yes	Mann-Whitney U test
59	2020	Lee		200					24/28 (86)			median	not given		537	4594	MISC	MISC	MISC vs MAS	yes	Mann-Whitney U test
60	2021	Valverde		200				50-200	176/222 (79)			median (IQR)	baseline	438 (420-846)			MISC	ICU admission		yes	Mann-Whitney U test
64	2020	Pereira						36-391				median (range)	not given		3660 (469-35976)	3295 (2567-8000)	MISC	MISC		yes	Mann-Whitney U test
65	2017	Fitzgerald	high: >500	**4984.4**				≤500	18/39 (46)			median (IQR)	peak	60214 (12000-130000)			cytokine release syndrome	longer organ dysfunction resolution		yes	Kaplan-Meier and Cox regression analysis
66	2020	Pouletty	highly elevated: >500	**1400**	0.957	80	100	not given	12/14 (85.7)			median (IQR)	not given	1067 (272-1709)	1760 (1693-2500)	295 (165-536)	Kawa- COVID-19	severity	ROC: combined with age >5 years	yes	ROC curves, Mann-Whitney U test
68	2020	Kurokawa		1000					26 (37.7)			frequency	baseline				allogeneic HCT	stage-3 AKI		yes	Cox regression model
69	2019	Horvat		**373**	0.88 (0.79-0.97)							median (IQR)	peak	49 (17.2-153.3)			hospitalized	90-day mortality		yes	ROC curves with 1000 bootstrap replicates
73	2020	Clark										mean ± SD	baseline		171 ± 57	678 ± 107	COVID-19	complete KD		yes	Mann-Whitney test
74	2017	Tonial		300					8/20 (40)			median (IQR)	baseline	172 (118.3-514)	454.4 ± 309.7	91.9 ± 6	sepsis	fewer		yes	Student's t-test or ANOVA
77	2021	Tonial		**135**	0.785 (0.733-0.830)	96	49					median (IQR)	peak	149.5 (81.7-377.2)	607 (217-1251)	138 (78-296)	sepsis	mortality		yes	ROC curve (Youden's index), nonparametric Mann-Whitney U test
78	2020	Pal		50000				10-118				mean ± SD	not given	41785 ± 41448			MAS	mortality		yes	Pearson's Chi-square test
80	2020	Tonial										median (IQR)	not given	150.5 (82.25-362)	586 (226-1093)	138 (80.5-287)	sepsis	mortality		yes	Mann-Whitney U test

#	year	first author	ferritin definition	ferritin threshold	AUC (95%CI)	sensitivity (%)	specificity (%)	normal range	increased (%)	normal (%)	decreased (%)	ferritin statistics	timing	overall statistics	case/intervention	control/comparator	diagnosis/condition	outcome	analysis description	significancy	analysis
81	2021	Klymet										median (IQR)	baseline		625 (103-8433)	310 (48.5-5546)	MISC	PICU admission		yes	nonparametric Mann-Whitney U test
83	2017	Carcillo										median (IQR)	peak		670 (240-2610), 885 (285-3205), 1100 (390-4770)	200 (120-420), 185 (100-360)	sepsis	inflammatory MOF phenotypes	MOF with inflammation phenotypes, immunoparalysis associated MOF, thrombocytopenia associated MOF vs single organ failure, MOF without inflammation phenotypes	yes	Wilcoxon-Mann-Whitney rank-sum test
85	2019	Simon		**1210**	0.89 (0.74-1.04)	88	85	≤1000	7/18 (38.9)			mean ± SD	peak	2025 ± 6233	3752 ± 9245	874 ± 2369	sepsis	DNA viremia		yes	ROC curve, unpaired t-test
88	2016	Al-Ghananim	iron deficiency for term infant: <15	15						26/26 (100)		mean ± SD	baseline	143 ± 126			very low birth weight infants				
89	2012	Demirkol	hyperferritinemia: >500	500					23/23 (100)			median (range)	not given	6341 (765-100000)	40802 (16348-65256)	5054 (765-100000)	secondary HLH/sepsis/MODS/MAS	mortality		no	Mann-Whitney U
91	2017	Carcillo	MAS: >500	**1980**	0.878 (0.751-1.000)	75	92		13/100 (13)			frequency	baseline				severe sepsis	mortality		yes	ROC curve (Youden index)
94	2021	Aydin	MAS: >684	684								mean ± SD	baseline		17863 ± 21846	753 ± 586	MAS due to	MAS	MAS vs MISC	yes	Mann-Whitney U test
95	2019	Cui	hyperferritinemia: >500	**500**	0.767 (0.633-							median (IQR)	baseline		2689 (1554-7142)	1025.2 (682.2-	sepsis	sepsis-		yes	ROC curve (Youden index),
96	2016	Ellis		500					69/110			median (range)	not given		17794 (754-522000)	4139 (42-30346)	dengue	dengue-		yes	conditional logistic regression
97	2021	Abrams										median (IQR)	peak	463 (225-911)	626 (350-1171)	289 (156-529)	MISC	ICU admission, shock, decreased cardiac function	ICU admission on first day vs no ICU admission	yes	multivariable logistic regression
98	2018	Goldman		10000								median (IQR)	peak		47500 (24016-	11884 (3130-	HLH	mortality		yes	Fisher exact test
99	2011	Bennett		3000					68/171 (39.8)			frequency	peak				ICU	ICU admission, mortality		yes	Tarone's test for the trend, Cox regression model
101	2012	Amin	latent iron deficiency: <76, normal iron: 76-400, iron	76, 400				76-400	26/140 (18.6)	75/140 (53.6)	30/140 (21.4)	frequency	baseline				very preterm infants				
102	2021	Cattalini										median (IQR)	baseline		563.8 (250-1068)	227 (147-449)	KD	KawaCOVID	KawaCOVID vs KD	yes	Mann-Whitney test
103	2018	Ghosh		200				50-300	23/36		13/36	median (IQR)	baseline	581 (287-1283)	763 (480-1820)	415 (262-852)	septic shock	mortality		no	multivariate analysis
104	2016	Cui										mean ± SD	baseline		35803 ± 5826	36290 ± 6205	secondary HLH				
106	2020	Deep		**per 100-unit**								median (IQR)	baseline		1107 (393-2668)	426 (209-958)	MISC	severe AKI	severe AKI vs	yes	multivariable logistic regression
107	2008	Mäkelä										mean (95%CI)	baseline		148.2 (100.7-218.2)	239.5 (135.2-	very preterm	need for RBC	hematocrit <0.3 vs	no	mixed model analysis of variance
108	2008	Allen	hyperferritinemia: ≥500	**10000**	0.92 (0.88-0.95)	90	96					median (range)	peak		15830 (994-189721)		HLH	HLH		yes	ROC curve
109	2021	Jat	increased: >60 (until 9 years), >300 (10-12 years)	60, 300					56/95 (58.9)			median (IQR)	not given	144 (80.1-290)	397.9 (148-879.2)	132 (80.1-196)	COVID-19	moderate-severe disease	moderate-severe vs asymptomatic-mild	no	Mann–Whitney test
110	2017	Ochiai	hyperferritinemia: ≥500	500					24/176 (13.6)			frequency	peak				very low birth weight infants	surgical ligation for patent ductus arteriosus, sepsis and moderate or severe states of bronchopulmonary dysplasia		yes	multiple and logistic regression analysis
113	2007	Garcia		**500**		64	80	200-500	12/36 (33.3)	11/36 (30.6)	13/36 (36.1)	median (IQR)	baseline	303 (21-2210)			severe sepsis, septic shock	mortality	log	yes	regression analysis
114	2021	Sa										median (IQR)	peak		640 (1400)	549 (871)	MISC	neurology symptom		no	not stated
115	2014	Minoia						18-300				median (IQR)	baseline		8235 (2048-22977)	900 (171-2968)	sJIA	MAS	before vs onset of MAS	yes	Mann-Whitney U test
124	2004	Haiden										median (IQR)	baseline		73.6 (34.3-99.9)	97.5 (60.8-126.0)	extremely low birth weight infants				
127	2003	Jacobs										mean ± SD	baseline		117.6 ± 16.2	134.4 ± 27.6	bronchiolitis, anemia				

all ferritin values expressed in ng/mL unit

AKI: acute kidney injury, AUC: area under the curve, COVID-19: coronavirus disease 2019, DIC: disseminated intravascular coagulation, ELISA: enzyme-linked immunosorbent assay, FS: febrile seizure, HBD: hepatobiliary dysfunction, HCT: hematopoetic cell transplantation, HF: heart failure, ICU: intensive care unit, IEI: inborn errors of immunity, IPH: idiopathic pulmonary hemosiderosis, HLH: hemophagocytic lymphohistiocytosis, KD: Kawasaki disease, MAS: macrophage activation syndrome, MISC: multisystem inflammatory syndrome in children, MODS: multiple organ dysfunction syndrome, MOF: multiple organ failure, PIMS-TS: paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2, PCR: polymerase chain reaction, ROC: receiver operating characteristic, SARS-CoV 2: severe acute respiratory syndrome coronavirus 2, sJIA: systemic juvenile idiopathic arthritis, TPE: therapeutic plasma exchange, VL: visceral leishmaniasis